Skip to main content

Intraoperative Intravenous Methadone Versus Non-Methadone Opioid Analgesia in Instrumented Spinal Fusion: A GRADE-Guided Systematic Review and Meta-Analysis

In brief

Intraoperative methadone reduces 24-hour opioid use after spinal fusion

Across five trials involving 364 patients, methadone reduced opioid use in the first 24 hours after spinal fusion; pain scores were also lower through 72 hours in adults. The pain differences were around one point, but could be too small to matter clinically, and evidence on side effects was limited. Larger safety trials are needed before routine use.

Journal
Journal of clinical medicine (Q1)
Published
30 October 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Ahmed Abu-Zaid, Reem B Alhajri, Ghalyah H Alsuhail, Faisal R Alabkal, Fatmah Y Boshehri, Mohammad A Alshammari, et al.
PMID
43030614
DOI
10.3390/jcm15218470

Why clinicians should know about it

  • Picked for Spine Surgery (top studies of the week, 15 November 2026): Systematic review of analgesia after instrumented spinal fusion
  • Picked for Anesthesiology and Pain Medicine (top studies of the week, 15 November 2026): Meta-analysis of intraoperative methadone for postoperative pain and opioid use

Abstract

Background: Instrumented spinal fusion is among the most painful surgical procedures. Methadone, a long-acting μ-opioid receptor agonist with N-methyl-D-aspartate receptor antagonism, may provide more sustained analgesia than shorter-acting intraoperative opioids. Methods: PubMed, Scopus, Web of Science, and the Cochrane Library were searched through August 2026 for randomized trials in adults or adolescents undergoing instrumented spinal fusion that compared intraoperative intravenous methadone with a shorter-acting intraoperative opioid. Random-effects meta-analysis, the Cochrane Risk of Bias 2 tool, GRADE, and published minimal clinically important differences (MCIDs) were used. Results: Five trials (364 participants; three in adults and two in adolescents) were included. Methadone reduced pain intensity at 24 h (MD -1.06, 95% CI -2.03 to -0.09; three trials), 48 h (MD -1.52, 95% CI -2.36 to -0.67), and 72 h (MD -1.04, 95% CI -1.91 to -0.17; two adult trials each); point estimates approximated the 1-point MCID, but confidence intervals included clinically unimportant differences. Opioid consumption was lower at 24 h (SMD -0.50, 95% CI -0.79 to -0.21; four trials; I2 = 0%), corresponding to relative reductions of 17% to 52% in the individual trials, but not at 48 h. Vomiting did not differ (RR 1.10, 95% CI 0.72 to 1.70). Respiratory events were rare, inconsistently defined, and not pooled. Certainty was moderate for 24-h opioid consumption and low or very low for all other outcomes. Conclusions: In adults undergoing instrumented spinal fusion, a single intraoperative dose of intravenous methadone may modestly reduce postoperative pain at 24 h and opioid consumption, but the clinical importance of these effects is uncertain; the evidence in adolescents is limited to two small trials, and adverse events were insufficiently reported. Methadone should be regarded as an optional, monitored component of multimodal analgesia rather than routine practice until larger trials powered for safety and longer-term opioid use are available.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.